Back to today’s briefing

Story perspectives

Dr. Vinay Prasad Returns to FDA Amid Biotech Concerns

8/9/2025

27 3

Summary

Story summary

Dr. Vinay Prasad is back at the FDA, taking the helm of the Center for Biologics Evaluation and Research after a brief resignation under political pressure. His return stirs worries about regulatory consistency and investor confidence in biotech, especially in gene therapy and vaccine approvals. While his evidence-driven methods promise long-term trust, they may also spark immediate uncertainty.

1 of 1

Story summary

Dr. Vinay Prasad is back at the FDA, taking the helm of the Center for Biologics Evaluation and Research after a brief resignation under political pressure. His return stirs worries about regulatory consistency and investor confidence in biotech, especially in gene therapy and vaccine approvals. While his evidence-driven methods promise long-term trust, they may also spark immediate uncertainty.